Phase II trial of the phosphatidyinositol-3 kinase (PLIK) inhibitor buparlisib (BKM120) in recurrent glioblastoma

被引：4
|
作者：
Wen, Patrick Y.
Yung, W. K. Alfred
Mellinghoff, Ingo K.
Ramkissoon, Shakti
Alexander, Brian Michael
Rinne, Mikael L.
Colman, Howard
Omura, Antonio MarcIllo Paduia
DeAngelis, Lisa Marie
Gilbert, Mark R.
De Groot, John Frederick
Cloughesy, Timothy Francis
Chi, Andrew S.
Lee, Eudocia Quant
Nayak, Lakshmi
Batchelor, Tracy
Chang, Susan Marina
Prados, Michael
Reardon, David A.
Ligon, Keith L.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2019
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
    Rachel Goodwin
    Derek Jonker
    Eric Chen
    Hagen Kennecke
    Michael Cabanero
    Ming-Sound Tsao
    Michael Vickers
    Caryn Bohemier
    Howard Lim
    Heather Ritter
    Dongsheng Tu
    Lesley Seymour
    Investigational New Drugs, 2020, 38 : 1077 - 1084
  • [42] The Phosphatidylinositol-3-Kinase Inhibitor BKM120 Impairs Proliferation and Induces Pro-Apoptotic Effects In Acute Myeloid Leukemia
    Allegretti, Matteo
    Ricciardi, Maria Rosaria
    Vincenzi, Martina
    Licchetta, Roberto
    Mirabilii, Simone
    Amadori, Sergio
    Foa, Robin
    Tafuri, Agostino
    BLOOD, 2013, 122 (21)
  • [43] A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
    McRee, Autumn J.
    Sanoff, Hanna K.
    Carlson, Cheryl
    Ivanova, Anastasia
    O'Neil, Bert H.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1225 - 1231
  • [44] Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma
    Kirstein, Martha M.
    Boukouris, Aristeidis E.
    Pothiraju, Deepika
    Buitrago-Molina, Laura E.
    Marhenke, Silke
    Schuett, Jutta
    Orlik, Johanna
    Kuehnel, Florian
    Hegermann, Jan
    Manns, Michael P.
    Vogel, Arndt
    LIVER INTERNATIONAL, 2013, 33 (05) : 780 - 793
  • [45] A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
    Autumn J. McRee
    Hanna K. Sanoff
    Cheryl Carlson
    Anastasia Ivanova
    Bert H. O’Neil
    Investigational New Drugs, 2015, 33 : 1225 - 1231
  • [46] Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
    Wen, Patrick Y.
    Touat, Mehdi
    Alexander, Brian M.
    Mellinghoff, Ingo K.
    Ramkissoon, Shakti
    McCluskey, Christine S.
    Pelton, Kristine
    Haidar, Sam
    Basu, Sankha S.
    Gaffey, Sarah C.
    Brown, Loreal E.
    Martinez-Ledesma, Juan Emmanuel
    Wu, Shaofang
    Kim, Jungwoo
    Wei, Wei
    Park, Mi-Ae
    Huse, Jason T.
    Kuhn, John G.
    Rinne, Mikael L.
    Colman, Howard
    Agar, Nathalie Y. R.
    Omuro, Antonio M.
    DeAngelis, Lisa M.
    Gilbert, Mark R.
    de Groot, John F.
    Cloughesy, Timothy F.
    Chi, Andrew S.
    Roberts, Thomas M.
    Zhao, Jean J.
    Lee, Eudocia Q.
    Nayak, Lakshmi
    Heath, James R.
    Horky, Laura L.
    Batchelor, Tracy T.
    Beroukhim, Rameen
    Chang, Susan M.
    Ligon, Azra H.
    Dunn, Ian F.
    Koul, Dimpy
    Young, Geoffrey S.
    Prados, Michael D.
    Reardon, David A.
    Yung, W. K. Alfred
    Ligon, Keith L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (09) : 741 - +
  • [47] The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro
    Amrein, Lilian
    Shawi, May
    Grenier, Jeremy
    Aloyz, Raquel
    Panasci, Lawrence
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (01) : 247 - 252
  • [48] Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
    Grana, B.
    Burris, H. A.
    Ahnert, J. Rodon
    Razak, A. R. Abdul
    De Jonge, M. J.
    Eskens, F.
    Siu, L. L.
    Ru, Q. C.
    Homji, N. F.
    Demanse, D.
    Di Tomaso, E.
    Cosaert, J. G. C. E.
    Quadt, C.
    Baselga, J.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma
    Younes, Anas
    Salles, Gilles
    Bociek, R. Gregory
    Martinelli, Giovanni
    Caballero, Dolores
    Gonzalez Barca, Eva
    Mukherjee, Nabanita
    Williams, Lisa
    Herbst, Fabian
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2014, 124 (21)
  • [50] Phase I dose escalation clinical trial of the P13K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC)
    Dees, E. C.
    Marcom, P. K.
    Snavely, A.
    Noe, J.
    Anders, C. K.
    Blackwell, K.
    Kimmick, G.
    Reeder-Hayes, K.
    Rosenstein, D.
    Perou, C. M.
    Carey, L. A.
    CANCER RESEARCH, 2013, 73
12345